AVIR (Atea Pharmaceuticals) Total Liabilities: $33.37 Mil (As of Mar. 2026)


AVIR Atea Pharmaceuticals Inc AVIR
24 GF Score
Price $4.49
! 3 Warning Signs
View Full Analysis

What is Atea Pharmaceuticals Total Liabilities?

Atea Pharmaceuticals AVIR +3.34% 24 Total Liabilities is $33.37 Mil as of Mar. 2026. GuruFocus rates AVIR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Atea Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $33.37 Mil.

Atea Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2025 ($27.18 Mil) to Dec. 2025 ($39.78 Mil) but then declined from Dec. 2025 ($39.78 Mil) to Mar. 2026 ($33.37 Mil).

Atea Pharmaceuticals's annual Total Liabilities declined from Dec. 2023 ($39.78 Mil) to Dec. 2024 ($25.80 Mil) but then increased from Dec. 2024 ($25.80 Mil) to Dec. 2025 ($39.78 Mil).


Atea Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Atea Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atea Pharmaceuticals Total Liabilities Chart

Atea Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 62.82 26.14 39.78 25.80 39.78

Atea Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.88 27.19 27.18 39.78 33.37
AVIR
24GF Score
Atea Pharmaceuticals Inc AVIR
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atea Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Atea Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=315.218-275.434
=39.78

Atea Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=267.076-233.709
=33.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $33.37 Mil mean?
Atea Pharmaceuticals (AVIR) has a Total Liabilities of $33.37 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Atea Pharmaceuticals and its competitors.
Is Atea Pharmaceuticals' Total Liabilities too high?
Atea Pharmaceuticals' current Total Liabilities is $33.37 Mil. Overall, Atea Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Atea Pharmaceuticals' Total Liabilities compare to IMRX and PROK?
Atea Pharmaceuticals' Total Liabilities of $33.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Atea Pharmaceuticals and its competitors. Atea Pharmaceuticals's current Total Liabilities is $33.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atea Pharmaceuticals stock overvalued right now?
Atea Pharmaceuticals (AVIR) has a current Total Liabilities of $33.37 Mil. The current Total Liabilities is $33.37 Mil. Atea Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Atea Pharmaceuticals (AVIR), the current Total Liabilities is $33.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atea Pharmaceuticals Business Description

Address 225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
24GF Score

Get the complete analysis for AVIR

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.49
Price